Loading organizations...
Loading organizations...
22NW is a specialist microcap investment firm, employing a focused, value-oriented strategy within the United States equity market. It makes long-term investments in undervalued microcap securities, actively capturing structural mispricings. This approach leverages performance dispersion inherent to microcaps through diligent fundamental analysis.
Founded in 2015 by Aron English, 22NW leverages its founder's extensive microcap experience. English possesses over 18 years in this asset class, including tenure as Director of Research at RBF Capital LLC. This deep pedigree within small-cap management informed his insight to establish a firm exclusively focused on the microcap universe.
22NW serves investors seeking targeted exposure to microcap market opportunities. The firm's vision is to deliver compelling investment performance by consistently applying niche expertise and disciplined value principles. It aims to generate substantial long-term returns for its partners through specialized knowledge and active engagement.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 9, 2023 | Lifecore Biomedical | $38.8M Series A | 22NW Fund, Legion Partners | 325 Capital, Cove Street Partners, Wynnefield Capital |